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A B S T R A C T
Extensive multiple-age cohort human papillomavirus (HPV) vaccination has proved to be highly effective. We
aimed to determine the 8-year population impact of a female single-age cohort HPV vaccination programme on
the incidence of anogenital warts (AGW). In 2008, Catalonia initiated a school-based quadrivalent HPV vacci-
nation programme targeting 11-year-old girls, achieving coverage over 80%. Data on diagnoses of AGW and
genital herpes were obtained from a population-based database of electronic health records covering 74% of the
population. The annual incidence rates from 2009 to 2016 were calculated, stratified by age and sex using
Joinpoint regression to estimate trends and annual percentage changes (APC). Among women aged 16–19 years,
the AGW incidence decreased by 61% from 2012 to 2016 (APC −19.4%; 95% CI: −30.0 to −7.3). In contrast,
the incidence of genital herpes in same-aged women increased throughout the study period (APC 11.1%; 95% CI:
7.2–15.2). Among men aged 20–22 years, the increasing incidence of AGW shifted to a downward trend in 2013
(APC 2009–2013: 17.0%; 95% CI: 8.2–26.5; and APC 2013–2016: −4.5%; 95% CI: −14.6 to 6.9). A similar
pattern was observed among men aged 23–25 years (APC 2009–2014: 16.0%; 95% CI: 12.0–20.2; and APC
2014–2016: −6.0%; 95% CI: −18.4 to 8.3). In contrast to AGW, among men aged 20–25 years, the incidence of
genital herpes increased over this period. Our study strongly suggests that a single-cohort HPV vaccination
strategy with high vaccine uptake not only provides direct benefit in the vaccinated cohorts but also extends
protection through a herd effect to unvaccinated men.
1. Introduction
Anogenital warts (AGW) are the first clinical outcome allowing as-
sessment of the impact of the quadrivalent HPV vaccine, as they occur
within few months after HPV infection (Garland et al., 2009). Data from
several high-income countries implementing a multiple-age cohort
(MAC) quadrivalent HPV vaccination programme have confirmed a fall
in AGW diagnoses among targeted girls and women (Ali et al., 2013a;
Ali et al., 2013b; Baandrup et al., 2013; Bauer et al., 2012; Cocchio
et al., 2017; Dominiak-Felden et al., 2015; Flagg and Torrone, 2018;
Leval et al., 2012; Oliphant et al., 2017; Smith et al., 2015; Thöne et al.,
2017), with herd effects in men depending on the vaccine coverage
(Drolet et al., 2019). However, data on the population-level impact of a
single-cohort strategy on the incidence of AGW are limited to a single
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study in Canada, and no herd effects in unvaccinated men have been
described to date (Guerra et al., 2016).
In September 2008, Catalonia, a region of 7.5 million inhabitants in
northeast Spain, started a school-based, single-age cohort HPV vacci-
nation programme targeting 11-year-old girls and offering the quad-
rivalent HPV vaccine free of charge, except for the 2010–2011 cam-
paign when the bivalent vaccine was used. More specifically, in
2010–2011, the bivalent vaccine was administered throughout
Catalonia except for Barcelona city (20% of girls approximately), where
the quadrivalent vaccine was administered due to surplus vaccines from
previous years. The use of the quadrivalent vaccine was resumed in
2011–2012 with the exception of a few municipalities that used the
surplus bivalent vaccine in that campaign (28% of girls), and continued
until 2017–2018 when the nonavalent HPV vaccine was administered.
During the first 9 years of the HPV vaccination programme, the overall
coverage in Catalonia was over 80% (Borràs-López et al., 2017;
Ministerio de Sanidad, n.d.). In Spain, vaccine uptake outside the pro-
gramme is uncommon and is estimated to be< 1% among women up to
45 years of age [Merck Sharp & Dohme, personal communication].
The quadrivalent HPV vaccine is the most commonly used vaccine
in Catalonia and targets high-risk HPV types 16 and 18, accounting for
71% of cervical cancer cases (de Sanjose et al., 2010), and low-risk HPV
types 6 and 11, which cause 90% of cases of AGW (Garland et al.,
2009). The bivalent HPV vaccine protects against HPV 16 and 18, and
the nonavalent HPV vaccine provides protection against the same types
as the quadrivalent vaccine and against five additional high-risk HPV
types, accounting for an additional 20% of cervical cancer cases
(Serrano et al., 2015).
In 2009, the Department of Health of Catalonia and the Catalan
Institute of Oncology established a monitoring plan that combined
several projects to evaluate the impact of HPV vaccination on disease
outcomes. One of these projects evaluates the impact of HPV vaccina-
tion on AGW and cervical pre-neoplastic lesions in the public primary
care centres of Catalonia. Here we present the first analysis where we
evaluate the population impact of the single-age cohort HPV vaccina-
tion programme in Catalonia on the incidence of AGW.
2. Methods
2.1. Population
The study population consisted of all residents of Catalonia aged
10–64 years assigned to a primary care centre of the ICS (Spanish ac-
ronym for the Catalan Institute of Health) from 2008 to 2016. The ICS is
the main primary health care public provider in Catalonia and offers
health care coverage to>74% of Catalonian residents. The reference
population was the population active in the Information System for
Research in Primary Care (SIDIAP database), a population-based data-
base of the anonymised electronic health records of patients assigned to
ICS primary care centres that is representative of the population of
Catalonia (García-Gil et al., 2011). The study population comprised 4
million individuals each year.
2.2. Data sources
The SIDIAP includes validated information on sociodemographic
variables, clinical diagnoses coded according to the International
Classification of Diseases 10th revision (ICD-10), clinical variables, la-
boratory test results, and prescriptions and pharmacy invoices coded
according to the Anatomical Therapeutic Chemical Classification (ATC)
(Bolíbar et al., 2012). Importantly, this comprehensive database in-
cludes data from patients seen by general practitioners, by the gynae-
cologists and midwifes at the network of centres for sexual and re-
productive health, and by the network of general practitioners trained
as referees for sexually transmitted infections (STI) in primary health
care, as well as data from patients seen at the main monographic STI
clinic of Catalonia. These publicly-funded services perform all non-
hospital based STI diagnoses in the public sector in Catalonia.
2.3. Case definition
Between January 2008 and December 2016, all records including
the following ICD-10 codes were retrieved: AGW (A63.0), genital
Chlamydia infection (A55 and A56), gonorrhoea (A54), and genital
herpes (A60). An episode of AGW was defined as incident if it was
preceded by a period of at least 12 months with no record of AGW;
episodes of genital Chlamydia infection and gonorrhoea were con-
sidered incident if they were preceded by a 2-month period with no
episodes; and episodes of genital herpes were classified as incident if
they were the first episode recorded in the SIDIAP, considering all
historical records. Data from the first year of the study period (2008)
were used only to exclude prevalent cases. An exploratory analysis
showed that the number of gonorrhoea diagnoses among women cov-
ered by the HPV vaccination programme (i.e. those younger than
20 years in 2016) was very low, especially in the first 3 years of the
study period (5–6 cases diagnosed annually). Additionally, there was a
marked rise (3-fold increase) in the incidences of other sexually trans-
mitted chlamydial diseases (A56) between 2014 and 2016, probably
reflecting changes in screening strategies, laboratory techniques and
reporting tools, which occurred in our setting during this period.
Therefore, in this study, we finally used only the incidence of genital
herpes as a control disease.
We also obtained data on drugs prescribed for AGW treatment to
examine AGW trends, including AGW diagnoses either by identification
of an ICD-10 record or a treatment prescription in a sensitivity analysis.
We extracted data on prescriptions of podophyllotoxin (ATC code
D06BB04), imiquimod (D06BB10), and sinecatechins (D06BB12).
Podophyllotoxin and sinecathechins are specific treatments for AGW
while imiquimod is also used in actinic keratosis and basal cell carci-
noma, conditions that are usually diagnosed in older people. We then
restricted the sensitivity analysis to trends in the young population (i.e.
persons younger than 30 years). Prescription data were available for
2009 onwards; therefore, to exclude prevalent cases in 2009, we cal-
culated the age- and sex-specific average proportion of prevalent cases
identified from prescriptions from 2010 to 2016 and applied these age-
and sex- specific proportions to the 2009 data. Since drugs used for
treatment of genital herpes are not specific, they were not extracted.
2.4. Statistical analyses
We estimated annual incidence rates per 100,000 population with
Wald confidence intervals (CI) at 95% in the population aged
10–64 years. Estimates of incidence rates were stratified by age and sex
(5-year age groups from 10 to 64 years, and groups aged 16–19, 20–22,
23–25, 26–27, and 28‐–29 years in the analysis of trends in younger
cohorts). To assess the effect of switching to the bivalent vaccine in
1 year of the HPV vaccination programme, incidence rate ratios (IRR)
were estimated to compare the incidence rate in: i) the last two birth
cohorts not covered by the HPV vaccination programme (1995–1996)
(reference category); ii) the first two birth cohorts vaccinated with the
quadrivalent vaccine (1997–1998); and iii) the only birth cohort vac-
cinated mainly with the bivalent vaccine (1999).
Analyses were conducted with the Joinpoint Regression Program
(version 4.4.0.0) (National Cancer Institute, Bethesda, MD) (National
Cancer Institute, n.d.) and the statistical software R version 3.2.3
(http://www.R-project.org). Joinpoint regression was used to estimate
trends in incidence by age and sex, which are reported as the annual
percentage change (APC) and its corresponding 95% CI for each seg-
ment. If a single segment is detected, the average annual percentage
change (AAPC) equals the APC for that segment. The Joinpoint Re-
gression Program models trends using the Monte Carlo permutation
method to select the optimum number of points at which incidence
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trends changed (National Cancer Institute, n.d.). To avoid overfitting
due the period length, the maximum number of joinpoints was limited
to 1. A 5% significance level was used.
This study was approved by the Clinical Research Ethics Committee
and the Institutional Review Board of the University Institute for
Primary Care Research (IDIAP) Jordi Gol (P15/106).
3. Results
3.1. Overall incidence of AGW and genital herpes
Between January 1st 2009 and December 31st 2016, a total of
33,933 new AGW cases were identified in individuals aged 10–64 years
(15,484 in women and 18,449 in men). The overall incidence rate of
AGW among women increased from 72 per 100,000 in 2009 to 107 in
2016, representing an average annual percentage increase of 5.2%
(95% CI, 2.8–7.6). Among men aged 10–64 years, the incidence of AGW
also increased significantly from 69 per 100,000 in 2009 to 135 in 2014
(APC 14.1%; 95% CI, 6.8–21.9), and then stabilised (APC 0.6%; 95% CI,
−21.3 to 28.7) with a resulting rate of 139 per 100,000 in 2016. In
2016, the incidence rate of AGW among women was highest in the
group aged 20–24 years, while the incidence among men was highest in
the group aged 25–29 years (Fig. 1).
The age- and sex-stratified analysis revealed a statistically sig-
nificant upward trend in the incidence of AGW from 2009 to 2016 in all
age groups except women under 25 years, women aged 60–64 years,
and men under 30 years (Supplementary Fig. 1).
During the study period, the overall incidence rate of genital herpes
significantly increased in both men and women (APC 9.8%; 95% CI,
7.5–12.2, and APC 10.8%; 95% CI, 8.8–12.8, respectively) (data not
shown).
3.2. Incidence of AGW and genital herpes among the population under
30 years
Fig. 2 shows the rates of AGW and genital herpes among young
women (Fig. 2A) and men (Fig. 2B) by age group. The incidence of
AGW among women aged 16–19 years increased nonsignificantly from
2009 to 2012 (APC 21.1%; 95% CI, −0.2 to 46.8) and subsequently
significantly declined from 194 per 100,000 in 2012 to 75 in 2016 (61%
reduction; APC −19.4%; 95% CI, −30.0 to −7.3) (Fig. 2A). Supple-
mentary Table 1 shows the potential vaccine received by women aged
16–19 years during the study period. In contrast, the incidence of
genital herpes among women in the same age group increased sig-
nificantly from 2009 to 2016 (APC 11.1%; 95% CI, 7.2–15.2). The in-
cidence rates of both AGW and genital herpes among women aged
20–22 years, 23–25 years, 26–27 years and 28–29 years increased
significantly over the study period.
Among men aged 16–19 years, the incidence rates of AGW were
quite lower than those among same-aged women and a non-significant
increasing trend was observed from 2009 to 2016 (APC 4.2%; 95% CI,
−3.4 to 12.4) (Fig. 2B). Among men aged 20–22 years, the incidence of
AGW significantly increased from 2009 to 2013 (APC 17.0%; 95% CI,
8.2–26.5) and then decreased through 2016, although this change was
not statistically significant (APC −4.5%; 95% CI, −14.6 to 6.9). A si-
milar pattern was observed among men aged 23–25 years, with a sig-
nificant increasing trend from 2009 to 2014 (APC 16.0%; 95% CI,
12.0–20.2) followed by a non-significant decline through 2016 (APC
−6.0%; 95% CI, −18.4 to 8.3). In contrast to these changes in the
trends for AGW, rates of genital herpes in both men aged 20–22 years
and 23–25 years significantly increased over the study period. The in-
cidence of both AGW and genital herpes significantly increased from
2009 to 2016 among men aged 26–27 years, and the incidence of AGW
significantly increased from 2009 to 2013 and then stabilised among
men aged 28–29 years, while the incidence of genital herpes increased
throughout the study period.
3.3. Sensitivity analysis
Table 1 shows the analyses of time trends in the incidence of AGW,
including only registered diagnoses and considering both registered
diagnoses and/or treatment prescriptions. The addition of confirmed
diagnoses through treatment prescriptions increased incident cases by
23% (during the study period, the incidence rate in individuals aged
16–29 years increased from 235 per 100,000 when registered diagnoses
were analysed, to 289 per 100,000 when both registered diagnoses and
treatment prescriptions were included) but yielded similar results in the
trend analyses. Among women, trend analyses by age group were si-
milar with few exceptions: among women aged 16–19 years the sig-
nificant downward trend in AGW started a year later (2013) with a
somewhat higher average decrease, and among women aged
23–25 years and 28–29 years, the slightly increasing trend was not
statistically significant. Among men, the addition of treatment pre-
scriptions resulted in similar trends with the following exceptions:
among men aged 16–19 years, there was a non-significant increasing
trend from 2009 to 2011, which then stabilised through 2016; among
men aged 20–22 years, the decreasing trend from 2013 to 2016 reached
statistical significance; among men aged 23–25 years, the increasing
trend ended a year sooner, in 2013, and then stabilised; and among men
aged 28–29 years, an increasing trend was detected over the study
period.
3.4. Incidence of AGW and genital herpes by birth cohort
Table 2 shows the age-specific IRR of AGW and genital herpes
among women aged 16–19 years in the last two birth cohorts not
covered by the HPV vaccination programme (1995–1996), the first two
birth cohorts vaccinated with the quadrivalent vaccine (1997–1998),
and the only birth cohort vaccinated mainly with the bivalent vaccine
(1999). Birth cohorts vaccinated with the quadrivalent vaccine showed
a lower incidence of AGW than unvaccinated cohorts at the age of 16,
17, 18 and 19 years, whereas no differences were observed in the in-
cidence rates of genital herpes between those cohorts at the same ages.
On the other hand, the birth cohort vaccinated mainly with the bivalent
vaccine showed a lower incidence of AGW than unvaccinated cohorts;
this difference was not statistically significant in individuals aged
16 years but reached statistical significance in those aged 17 years.
Fig. 1. Age-specific incidence rates of anogenital warts by sex in 2016.
Shadowed areas indicate 95% confidence intervals of the incidence rates.
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Fig. 2. Incidence rates of anogenital warts and genital herpes from 2009 to 2016 among women (A) and men (B) aged 16–29 years. Shadowed areas indicate 95%
confidence intervals of the incidence rates. The area painted in Fig. 2A (age group 16-19) indicates that girls are partially eligible for the HPV vaccination program
(starting in 2013, when only 16-year-olds could have received the HPV vaccine, and ending in 2016, when 16- to 19-year-olds were covered by the HPV vaccination
program).
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4. Discussion
This study demonstrates a substantial reduction in the incidence of
AGW among women eligible for the HPV vaccination programme in
Catalonia. From 2012 to 2016, AGW incidence rates decreased by 61%
among women aged 16–19 years who were eligible for HPV vaccina-
tion, but increased or remained stable among older women, who were
all non-eligible for HPV vaccination. Among men, the incidence of AGW
showed an upward trend in all groups except those aged 20–22 years
and 23–25 years, in which the increasing incidence shifted to a
downward trend in 2013 and 2014, respectively. By contrast, the in-
cidence of genital herpes in young men and women showed increasing
trends during the study period.
Our findings show a larger decrease in AGW among eligible women
than that reported in a study assessing the impact of the single-cohort
vaccination programme in Ontario (Canada), which reported a 6.5%
decline in AGW incidence among women aged 18–20 years between
pre-vaccination and post-vaccination periods (Guerra et al., 2016). This
discrepancy could be explained by differences in the estimation of the
reduction, as we calculated the decrease between the last cohorts not
eligible for HPV vaccination and the eligible cohorts, rather than that
between pre- and post-vaccination periods. The differences may also be
due to the lower vaccine uptake in Ontario in the first four years of the
programme (51%–58%) (Guerra et al., 2016). Our results are similar to
those recently reported in a meta-analysis in countries vaccinating MAC
with coverage ≥50% after 1–4 years of vaccine introduction, which
found a 64% reduction among women aged 15–19 years (Drolet et al.,
2019). This suggests that the overall effect of single-cohort vaccination
programmes could be similar to that of MAC strategies, although the
effects in countries adopting a MAC strategy become apparent much
sooner. Lastly, our findings are consistent with reductions seen in a
study performed in Valencia (Spain) that assessed individual-level
vaccination data and reported an effectiveness against AGW of the
quadrivalent vaccine (3-dose schedule) of 77% (Navarro-Illana et al.,
2017).
The shift to a downward trend in the incidence of AGW among
unvaccinated men aged 20–25 years strongly suggests an early herd
effect of the HPV vaccination programme, as the increasing incidence of
genital herpes indicate this is unlikely to be explained by changes in
sexual behaviour. Although the decreases were not yet statistically
significant, the shifts indicate that the increasing trend of AGW among
young men has at least been contained. Of note, men aged 16–19 years
had a low incidence of AGW with a non-significant time trend sug-
gesting a different pattern of sexual exposure compared with women in
the same age category. The age-specific figures for the incidence of
AGW by sex (Fig. 1) showed that rates among men were slightly moved
to older ages; therefore, it is likely that women eligible for HPV vac-
cination had older partners, consistent with the results found in our
Table 1
Sensitivity analysis. Comparison of time trends in the incidence of anogenital warts in the young population by age and sex, including only registered diagnoses (ICD-
10 code A63.0) and both diagnoses and/or treatment prescriptions, 2009–2016.
Age group Trends considering only registered diagnoses Trends considering both registered diagnoses and/or treatment prescriptions
Trend segment APC 95% CI p-value Trend segment APC 95% CI p-value
Women
16-19 2009-2012 21.1 -0.2 - 46.8 0.051 2009-2013 11.7 -1.3 - 26.5 0.066
2012-2016 -19.4 -30 - -7.3 0.016 2013-2016 -26.1 -42.1 - -5.6 0.029
20-22 2009-2016 5.8 2.6 - 9.2 0.004 2009-2016 4.6 1.3-8 0.014
23-25 2009-2016 3.8 0.9 - 6.7 0.017 2009-2016 2.8 -0.1 - 5.8 0.057
26-27 2009-2016 7.7 3.4 - 12.1 0.004 2009-2016 7.1 3.2 - 11.2 0.004
28-29 2009-2016 5.5 1.1 - 10.2 0.022 2009-2016 4.6 0 - 9.4 0.051
Men
16-19 2009-2016 4.2 -3.4 - 12.4 0.232 2009-2011 35.4 -0.1 - 83.6 0.051
2011-2016 -1.5 -6.8 - 4.2 0.457
20-22 2009-2013 17 8.2 - 26.5 0.008 2009-2013 15.6 12.6 - 18.8 < 0.001
2013-2016 -4.5 -14.6 - 6.9 0.285 2013-2016 -4.5 -8.1 - -0.7 0.032
23-25 2009-2014 16 12 - 20.2 0.001 2009-2013 17.8 8.9 - 27.4 0.007
2014-2016 -6 -18.4 - 8.3 0.259 2013-2016 0.5 -9.6 - 11.8 0.884
26-27 2009-2016 14.8 9.4 - 20.4 <0.001 2009-2016 14.3 10 - 18.7 < 0.001
28-29 2009-2013 19.4 8.9 - 30.9 0.009 2009-2016 12.6 8 - 17.4 < 0.001
2013-2016 3.3 -9.1 - 17.3 0.478
Table 2
Age-specific incidence rates ratios (IRR) of anogenital warts and genital herpes by birth cohort among women aged 16–19 years.
Birth cohort Vaccination program Age (years)
16 17 18 19
N cases IRR (95% CI) N cases IRR (95% CI) N cases IRR (95% CI) N cases IRR (95% CI)
Anogenital warts
1995-1996a No vaccination 31 1.00 (Ref) 67 1.00 (Ref) 103 1.00 (Ref) 157 1.00 (Ref)
1997-1998b Quadrivalent 11 0.36 (0.17,0.69) 18 0.27 (0.16,0.45) 34 0.33 (0.22,0.48) 27 0.34 (0.22,0.50)
1999c Mainly bivalent 9 0.57 (0.25,1.15) 20 0.58 (0.34,0.94) - - - -
Genital herpes
1995-1996a No vaccination 13 1.00 (Ref) 33 1.00 (Ref) 73 1.00 (Ref) 72 1.00 (Ref)
1997-1998b Quadrivalent 22 1.68 (0.86,3.45) 40 1.21 (0.76,1.93) 63 0.86 (0.61,1.20) 41 1.11 (0.75,1.61)
1999c Mainly bivalent 13 1.94 (0.88,4.25) 26 1.52 (0.90,2.55) - - - -
a Not covered by the HPV vaccination program.
b Quadrivalent HPV vaccine eligible (estimated 3-dose coverage 80%).
c 78% of women bivalent HPV vaccine eligible; 22% of women quadrivalent HPV vaccine eligible (estimated 3-dose coverage 80%).
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study. Herd effects of HPV vaccination programmes in unvaccinated
men have been widely reported in high-income countries that vacci-
nated MAC (Ali et al., 2013a; Ali et al., 2013b; Bauer et al., 2012;
Dominiak-Felden et al., 2015; Flagg and Torrone, 2018; Smith et al.,
2015; Thöne et al., 2017; Bollerup et al., 2016) but, to our knowledge,
this is the first description of herd effects in unvaccinated men fol-
lowing a single-cohort strategy. Drolet et al. (2019) stated in their meta-
analysis that the magnitude of the decreases observed in unvaccinated
men depends on the overall proportion of people vaccinated in the
country, with no herd effects observed in men in countries with a low
proportion of vaccinated individuals (countries with a single-cohort
strategy or those with a MAC strategy and coverage under 50%). Fur-
thermore, a modelling study including data from Australia showed the
importance of catch-up cohorts in the achievement of herd effects
(Drolet et al., 2017). While we were able to observe the extended
benefit of a single-cohort HPV vaccination strategy in unvaccinated
men, vaccinating additional cohorts could have had an additional,
faster impact in the population.
We also aimed to assess the effect of switching to the bivalent
vaccine in one year of the vaccination programme on the incidence of
AGW. We observed a significantly lower rate of AGW among 17-year-
olds, which could have several explanations. First, the cohort eligible
for the bivalent vaccine was not fully vaccinated with this vaccine, as
22% of women received the quadrivalent vaccine. Therefore, the birth
cohort was partially protected against AGW. Second, in this study, we
found herd effects in unvaccinated young men, raising the possibility
that females in the cohort who received primarily the bivalent vaccine
also received some herd protection from the quadrivalent vaccine given
to other cohorts. Lastly, the bivalent vaccine may have a protective
effect against AGW itself. Two ecological studies conducted in England
have suggested that the bivalent vaccine protects against AGW,
showing decreases in the incidence of AGW among young girls and
young heterosexual men that were associated with HPV vaccine cov-
erage (Canvin et al., 2017; Howell-Jones et al., 2013). By contrast,
studies assessing individual-level data on HPV vaccination in Spain and
the Czech Republic did not confirm a protective effect against AGW
(Navarro-Illana et al., 2017; Petráš and Adámková, 2015).
4.1. Study limitations and strengths
Our data cover only the public sector, and therefore the actual in-
cidence rates may be underestimated. In Catalonia, it is estimated that
29% of women and 30% of men aged 15–44 years have dual health
insurance coverage (i.e. both public and private health insurance)
(Generalitat de Catalunya, Departament de Salut, 2019). We performed
a sensitivity analysis including AGW diagnoses identified from treat-
ment prescriptions, as it is not uncommon for people visiting private
physicians to seek drug treatments covered by the publicly-funded
health system. The sensitivity analyses showed that 23% of incident
AGW cases diagnosed in young people had not been registered, but
yielded similar trends in vaccinated cohorts and in men aged
20–25 years. Therefore, considering the results of the sensitivity ana-
lysis and that the underestimation applies to the entire study period, we
believe it is unlikely that our results were affected by this potential
limitation. Furthermore, the herd effects observed in men were prob-
ably limited by the lack of data on sexual orientation in the SIDIAP
database. If we had been able to perform the analysis in men by sexual
orientation, we would have expected a greater decrease in heterosexual
men, with no decreases in homosexual men, as described by others (Ali
et al., 2013a; Chow et al., 2015).
Our study also has several strengths. First, we used a representative
database covering 74% of the general Catalonian population (García-
Gil et al., 2011). In addition, the database included medical records not
only from general practitioners, but also from all the sexual and re-
productive health services and STI clinics. Moreover, using genital
herpes as a well-documented control STI allowed us to differentiate
vaccination impact from potential changes in exposure over time. Fi-
nally, our analyses relied on registered clinical diagnoses of AGW, not
AGW treatments, which is important as the temporal trend analysis was
not influenced by changes in clinical practice during the study period.
5. Conclusion
We found that AGW substantially decreased among vaccinated co-
horts, confirming the early impact of a single-age cohort HPV vacci-
nation strategy. The shift to a downward trend in AGW in young men
strongly suggests an early herd effect of single-cohort HPV vaccination.
Although a MAC vaccination strategy is recommended to increase the
benefits of the HPV vaccination programme (World Health
Organization, 2017), the introduction of MAC may be hindered by
several factors, including affordability or problems with HPV vaccine
supply (UNICEF, 2018; WHO, 2019). Our results could help to envisage
the impact of a single-cohort vaccination programme, where a MAC is
currently not a feasible option.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ypmed.2020.106166.
CRediT authorship contribution statement
Maria Brotons: Conceptualization, Methodology, Writing - ori-
ginal draft. Laura Monfil: Software, Formal analysis, Visualization.
Esther Roura: Software, Formal analysis, Validation. Talita Duarte-
Salles: Writing - review & editing. Jordi Casabona: Writing - review
& editing. Luis Urbiztondo: Funding acquisition, Writing - review &
editing. Carmen Cabezas: Funding acquisition, Writing - review &
editing. F. Xavier Bosch: Writing - review & editing. Silvia de
Sanjosé: Writing - review & editing. Laia Bruni: Conceptualization,
Supervision, Writing - review & editing.
Declaration of competing interest
F. Xavier Bosch has received scientific advisory board fees, speaker's
fees, or travel grants from GlaxoSmithKline, Merck and Co., Inc. and
IMS Health and unrestricted institutional research grants from
GlaxoSmithKline and Merck and Co., Inc. The Cancer Epidemiology
Research Programme (with which Maria Brotons, Laura Monfil, Esther
Roura, F. Xavier Bosch, Silvia de Sanjosé and Laia Bruni are affiliated)
has received sponsorship for grants from Merck and Co., Inc. and GSK.
The rest of the authors declare no conflicts of interest.
Acknowledgements
To Xavi Castellsagué, who initiated this project and passed away in
2016. We acknowledge the SIDIAP, with special thanks to Maria Aragon
for technical support. The results of the “Monitorización y evaluación
del impacto de la introducción de nuevas estrategias preventivas del
cancer de cuello de útero en Catalunya” (0599S/7613/2010) project
are partially funded by the Department of Health of the Generalitat de
Catalunya. This study has been partially funded by Instituto de Salud
Carlos III through grant CM15/00061 Río Hortega (co-funded by
European Social Fund. ESF, investing in your future) and through the
CIBERESP CB06/02/0073 project (co-funded by European Regional
Development Fund. ERDF, a way to build Europe). With the support of
the Secretariat for Universities and Research of the Department of
Business and Knowledge of the Government of Catalonia, grants to
support the activities of research groups (SGR 2017-2019) number
2017SGR1718 and 2017SGR1085. We also thank CERCA Programme/
Generalitat de Catalunya for institutional support. The funding sources
had no role in the study design, data collection, analysis or inter-
pretation of the results, writing of the manuscript, or the decision to
submit the manuscript for publication.
M. Brotons, et al. Preventive Medicine 138 (2020) 106166
6
References
Ali, H., Donovan, B., Wand, H., Read, T.R.H., Regan, D.G., Grulich, A.E., et al., 2013a.
Genital warts in young Australians five years into national human papillomavirus
vaccination programme: national surveillance data. BMJ 346, f2032. https://doi.org/
10.1136/bmj.f2032.
Ali, H., Guy, R.J., Wand, H., Read, T.R., Regan, D.G., Grulich, A.E., et al., 2013b. Decline
in in-patient treatments of genital warts among young Australians following the
national HPV vaccination program. BMC Infect. Dis. 13, 140. https://doi.org/10.
1186/1471-2334-13-140.
Baandrup, L., Blomberg, M., Dehlendorff, C., Sand, C., Andersen, K.K., Kjaer, S.K., 2013.
Significant decrease in the incidence of genital warts in young Danish women after
implementation of a national human papillomavirus vaccination program. Sex.
Transm. Dis. 40, 130–135. https://doi.org/10.1097/OLQ.0b013e31827bd66b.
Bauer, H.M., Wright, G., Chow, J., 2012. Evidence of human papillomavirus vaccine-
effectiveness in reducing genital warts: an analysis of California public family plan-
ning administrative claims data, 2007-2010. Am. J. Public Health 102, 833–835.
https://doi.org/10.2105/AJPH.2011.300465.
Bolíbar, B., Fina Avilés, F., Morros, R., Garcia-Gil, M. del M., Hermosilla, E., Ramos, R.,
et al., 2012. SIDIAP database: electronic clinical records in primary care as a source of
information for epidemiologic research. Med. Clin. (Barc.) 138, 617–621. https://doi.
org/10.1016/j.medcli.2012.01.020.
Bollerup, S., Baldur-Felskov, B., Blomberg, M., Baandrup, L., Dehlendorff, C., Kjaer, S.K.,
2016. Significant reduction in the incidence of genital warts in young men 5 years
into the Danish Human Papillomavirus Vaccination Program for girls and women.
Sex. Transm. Dis. 43, 238–242. https://doi.org/10.1097/OLQ.0000000000000418.
Borràs-López, E., Urbiztondo-Perdices, L., Martínez-Marcos, M., Ibáñez, D., Cabezas-Peña,
C., 2017. La vacunació contra el virus del papil·loma humà a Catalunya: cobertures i
notificacions de sospita de reaccions adverses a vacunes. Butll Epidemiol. Catalunya
36, 137–143.
Canvin, M., Sinka, K., Hughes, G., Mesher, D., 2017. Decline in genital warts diagnoses
among young women and young men since the introduction of the bivalent HPV (16/
18) vaccination programme in England: an ecological analysis. Sex. Transm. Infect.
93, 125–128. https://doi.org/10.1136/sextrans-2016-052626.
Chow, E.P.F., Read, T.R.H., Wigan, R., Donovan, B., Chen, M.Y., Bradshaw, C.S., et al.,
2015. Ongoing decline in genital warts among young heterosexuals 7 years after the
Australian human papillomavirus (HPV) vaccination programme. Sex. Transm.
Infect. 91, 214–219. https://doi.org/10.1136/sextrans-2014-051813.
Cocchio, S., Baldovin, T., Bertoncello, C., Buja, A., Furlan, P., Saia, M., et al., 2017.
Decline in hospitalization for genital warts in the Veneto region after an HPV vac-
cination program: an observational study. BMC Infect. Dis. 17, 249. https://doi.org/
10.1186/s12879-017-2361-5.
de Sanjose, S., Quint, W.G., Alemany, L., Geraets, D.T., Klaustermeier, J.E., Lloveras, B.,
et al., 2010. Human papillomavirus genotype attribution in invasive cervical cancer:
a retrospective cross-sectional worldwide study. Lancet Oncol. 11, 1048–1056.
https://doi.org/10.1016/S1470-2045(10)70230-8.
Dominiak-Felden, G., Gobbo, C., Simondon, F., 2015. Evaluating the early benefit of
quadrivalent HPV vaccine on genital warts in Belgium: a cohort study. PLoS One 10,
e0132404. https://doi.org/10.1371/journal.pone.0132404.
Drolet, M., Laprise, J.-F., Brotherton, J.M.L., Donovan, B., Fairley, C.K., Ali, H., et al.,
2017. The impact of human papillomavirus catch-up vaccination in Australia: im-
plications for introduction of multiple age cohort vaccination and post-vaccination
data interpretation. J. Infect. Dis. 216, 1205–1209. https://doi.org/10.1093/infdis/
jix476.
Drolet, M., Bénard, É., Pérez, N., Brisson, M., Ali, H., Boily, M.-C., et al., 2019. Population-
level impact and herd effects following the introduction of human papillomavirus
vaccination programmes: updated systematic review and meta-analysis. Lancet 394,
497–509. https://doi.org/10.1016/S0140-6736(19)30298-3.
Flagg, E.W., Torrone, E.A., 2018. Declines in anogenital warts among age groups most
likely to be impacted by human papillomavirus vaccination, United States, 2006-
2014. Am. J. Public Health 108, 112–119. https://doi.org/10.2105/AJPH.2017.
304119.
García-Gil, M.D.M., Hermosilla, E., Prieto-Alhambra, D., Fina, F., Rosell, M., Ramos, R.,
et al., 2011. Construction and validation of a scoring system for the selection of high-
quality data in a Spanish population primary care database (SIDIAP). Inform. Prim.
Care 19, 135–145. https://doi.org/10.14236/jhi.v19i3.806.
Garland, S.M., Steben, M., Sings, H.L., James, M., Lu, S., Railkar, R., et al., 2009. Natural
history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of
a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J. Infect. Dis.
199, 805–814. https://doi.org/10.1086/597071.
Generalitat de Catalunya, Departament de Salut, 2019. Enquesta de Salut de Catalunya
2018. Principals indicadors ESCA2018.
Guerra, F.M., Rosella, L.C., Dunn, S., Wilson, S.E., Chen, C., Deeks, S.L., 2016. Early
impact of Ontario’s human papillomavirus (HPV) vaccination program on anogenital
warts (AGWs): a population-based assessment. Vaccine 34, 4678–4683. https://doi.
org/10.1016/j.vaccine.2016.08.020.
Howell-Jones, R., Soldan, K., Wetten, S., Mesher, D., Williams, T., Gill, O.N., et al., 2013.
Declining genital warts in young women in England associated with HPV 16/18
vaccination: an ecological study. J. Infect. Dis. 208, 1397–1403. https://doi.org/10.
1093/infdis/jit361.
Leval, A., Herweijer, E., Arnheim-Dahlström, L., Walum, H., Frans, E., Sparén, P., et al.,
2012. Incidence of genital warts in Sweden before and after quadrivalent human
papillomavirus vaccine availability. J. Infect. Dis. 206, 860–866. https://doi.org/10.
1093/infdis/jis405.
Ministerio de Sanidad, Consumo y Bienestar Social. Histórico de coberturas de
vacunación n.d. https://www.mscbs.gob.es/profesionales/saludPublica/
prevPromocion/vacunaciones/HistoricoCoberturas.htm (accessed May 2, 2020).
National Cancer Institute. Joinpoint. n.d.
Navarro-Illana, E., López-Lacort, M., Navarro-Illana, P., Vilata, J.J., Diez-Domingo, J.,
2017. Effectiveness of HPV vaccines against genital warts in women from Valencia,
Spain. Vaccine 35, 3342–3346. https://doi.org/10.1016/j.vaccine.2017.04.080.
Oliphant, J., Stewart, J., Saxton, P., Lo, M., Perkins, N., Ward, D., 2017. Trends in genital
warts diagnoses in New Zealand five years following the quadrivalent human pa-
pillomavirus vaccine introduction. N. Z. Med. J. 130, 9–16.
Petráš, M., Adámková, V., 2015. Impact of quadrivalent human papillomavirus vaccine in
women at increased risk of genital warts burden: population-based cross-sectional
survey of Czech women aged 16 to 40 years. Vaccine 33, 6264–6267. https://doi.
org/10.1016/j.vaccine.2015.09.071.
Serrano, B., de Sanjosé, S., Tous, S., Quiros, B., Muñoz, N., Bosch, X., et al., 2015. Human
papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in
female anogenital lesions. Eur. J. Cancer 51, 1732–1741. https://doi.org/10.1016/j.
ejca.2015.06.001.
Smith, M.A., Liu, B., McIntyre, P., Menzies, R., Dey, A., Canfell, K., 2015. Fall in genital
warts diagnoses in the general and indigenous Australian population following im-
plementation of a National Human Papillomavirus Vaccination Program: analysis of
routinely collected national hospital data. J. Infect. Dis. 211, 91–99. https://doi.org/
10.1093/infdis/jiu370.
Thöne, K., Horn, J., Mikolajczyk, R., 2017. Evaluation of vaccination herd immunity ef-
fects for anogenital warts in a low coverage setting with human papillomavirus
vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance
data. BMC Infect. Dis. 17, 564. https://doi.org/10.1186/s12879-017-2663-7.
UNICEF, 2018. Supply Division. Human Papillomavirus Vaccine Supply and Demand
Update. Copenhagen, UNICEF.
WHO, 2019. Meeting of the Strategic Advisory Group of Experts on Immunization,
October 2019: conclusions and recommendations. Wkly Epidemiol. Rec. 94,
550–551.
World Health Organization, 2017. Human papillomavirus vaccines: WHO position paper,
May 2017-recommendations. Vaccine 35, 5753–5755. https://doi.org/10.1016/j.
vaccine.2017.05.069.
M. Brotons, et al. Preventive Medicine 138 (2020) 106166
7
